MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK) is scheduled to announce its financial results for the 2009 first quarter on Thursday, May 7, 2009, before the market opens. At 9:00 a.m. (ET) on that day, MiddleBrook management will conduct a conference call to review results for the 2009 first quarter.

To listen live to the call, dial 1-800-813-8504 or 1-660-422-4526. A replay of the call will be available starting at approximately 11 a.m. on May 7 through 5 p.m. on May 14, 2009. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291, and enter the conference ID #94048404.

A live audio webcast of the conference call also will be available by going to the Investor Relations section of MiddleBrook's web site, www.middlebrookpharma.com. A replay of the webcast will be available starting at approximately 11 a.m. on May 7 through 5 p.m. on June 5, 2009.

MiddleBrook Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 4350

MiddleBrook Pharmaceuticals also announced today that on March 31, 2009, it granted options to purchase 3,500 shares of MiddleBrook's common stock to two (2) new employees as a material inducement for them to join MiddleBrook. The options were granted pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) and under MiddleBrook's New Hire Stock Incentive Plan, which was approved by MiddleBrook's Board of Directors on Sept. 26, 2008. The options have a per share exercise price equal to the closing price of MiddleBrook's common stock on the NASDAQ Global Market on the business day immediately preceding the grant date, a ten-year term and vesting over four years, with 25 percent of the options vesting one year from the grant date and 1/48th of the options vesting monthly thereafter. The options have a grant date of March 31, 2009.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We have developed a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. We are currently developing a portfolio of anti-infective PULSYS products. Our near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing which we believe will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG � the first and only FDA-approved once-daily amoxicillin. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

Grafico Azioni Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Middlebrook Pharmaceuticals (MM)
Grafico Azioni Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Middlebrook Pharmaceuticals (MM)